Promaxo, a US-based medical imaging, robotics, and AI technology company, has received IRB approval from WCG Clinical Services for a clinical study on its MRI system.
The approval will enable a multi-centre feasibility study of the Promaxo MRI System for prostate biopsy guidance. The first study site will be at the Mississippi Urology Clinic.
Dr. Amit Vohra, co-founder and CEO, said: “We are thrilled to have secured approval from WCG Clinical Services to conduct a clinical feasibility study of prostate biopsy guidance, an integral step in progressing Promaxo’s system.
“This study will further our advancements and comprehensive research methods, bringing us one step closer to introducing our MRI systems into physicians’ offices and ultimately enhance the quality of care for patients.”
Additionally, Promaxo welcomes Dr John D Adams, Jr. as its newest advisory board member. Adams is a urologist at Mississippi Urology Clinic and serves as a member of several industry organisations.
He said: “Having focused my career on being an active private practice urologist, I have seen first-hand how crucial it is to develop and deliver accessible strategies within prostate interventional protocols.
“I am excited to join Promaxo as an advisor at such a pivotal time in its development.”
This news follows Promaxo’s recent closing of its $4.17m series B-2 funding round.